Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Case Report Volume 4 Issue 8

Reversing Phenotype from Epithelial-Mesenchymal Transition (EMT) to Mesenchymal-Epithelial Transition (MET) with Eribulin: Case Report

Jai Bhagwan Sharma*

Medical Oncology, H.O.D. and Senior Consultant, Action Cancer Hospital, New Delhi, India

*Corresponding Author: Jai Bhagwan Sharma, Medical Oncology, H.O.D. and Senior Consultant, Action Cancer Hospital, New Delhi, India.

Received: July 22, 2020; Published: July 30, 2020

×

Abstract

 Breast cancer remains the most frequently diagnosed cancer in women and, despite significant improvements in treatment, it remains the second leading cause of death from cancer.

Keywords: Epithelial-Mesenchymal Transition (EMT); Mesenchymal-Epithelial Transition (MET); Eribulin

×

References

  1. Ankur S. “Triple Negative Breast Cancer: A Unique Type of Breast Cancer”. Reconstructive Surgery and Anaplastology1 (2017).
  2. Montemurro F., et al. “Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications”. Annals of Oncology 2013 24: 2715-2724.
  3. Maria CAS., et al. “Management of metastatic HER2-positive breast cancer: Where are we and where do we go from here?” Oncology2 (2016): 148-155.
  4. Shreshtha M., et al. “Epidemiology of breast cancer in Indian women”. Asia-Pacific Journal of Clinical Oncology 13 (2017): 289-295.
  5. Larionov AA. “Current Therapies for Human Epidermal Growth Factor Receptor 2-positive metastatic Breast Cancer”. Frontiers in Oncology 8 (2018): 89.
  6. Gurprataap SS., et al. “Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis”. Journal of Global Oncology6 (2016): 412-421.
  7. Andre F and Zielinski CC. “Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents”. Annals of Oncology6 (2012): 46-51.
  8. Twelves C., et al. “Efficacy of eribulin in women with metastatic cancer: a pooled analysis of two phase 3 studies”. Breast Cancer Research and Treatment 148 (2014): 553-561.
  9. Drakaki A and Sara AH. “HER2-Positive Breast Cancer: Update on New and Emerging Agents”. The American Journal of Hematology/Oncology4 (2015): 17-23.
  10. Araki K. “First report of Eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer”. The Breast 35 (2017): 78-84.
  11. Gorouhi F and Gluck S. “Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature”. Journal of Solid Tumors1 (2013).
  12. Menis J and Twelves C. “Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer”. Breast Cancer: Targets and Therapy 3 (2013): 101-111.
  13. Goto W., et al. “Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer”. Anticancer Research 38 (2018): 2929-2938.
  14. Yoshida T., et al. “Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states”. British Journal of Cancer 110 (2014): 1497-1505.
  15. Medici M and Fossile E. “Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report”. Oncology1 (2018): 3-5.
  16. Sallinas CA., et al. “Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature”. Journal of Clinical Oncology4 (2014): 21-24.
  17. Jordan MA., et al. “The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth”. Molecular Cancer Therapeutics 7 (2005): 1086-1095.
  18. Ramaswami R., et al. “Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund”. Future Oncology3 (2014): 363-376.
  19. Cortes J., et al. “Multiple modes of action of eribulin mesylate: Emerging data and clinical implications”. Cancer Treatment Reviews 70 (2018): 190-198.
  20. Yoshida T., et al. “Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states”. British Journal of Cancer 110 (2014): 1497-1505.
  21. Shaughnessy JO., et al. “Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer”. Future Oncology14 (2019): 1641-1653.
  22. Funahashi Y., et al. “Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models”. Cancer Science10 (2014): 1334-1342.
×

Citation

Citation: Jai Bhagwan Sharma. “Reversing Phenotype from Epithelial-Mesenchymal Transition (EMT) to Mesenchymal-Epithelial Transition (MET) with Eribulin: Case Report". Acta Scientific Cancer Biology 4.8 (2020): 27-30.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.018

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US